沈亨达

Cooley advised Luqa Ventures, a dermatology specialty company, on its sale of all issued and outstanding shares to China Medical System (0867.HK). Following the transaction, Luqa became a wholly-owned subsidiary of CMS. Luqa has an extensive portfolio of prescription medicines, medical devices, medical aesthetic solutions and skin care products that meets the diversified needs of consumers in China and provides the market with safe and effective solutions for a broad range of skin conditions. This acquisition marked CMS’s first foray into the medical aesthetic market. Partner James Lu led the Cooley team advising Luqa Ventures on the transaction.

Cooley advised InnoCare Pharma, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class and best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide, on its transformational license agreement with Zenas BioPharma, granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Cooley advised Hello Group, a leading player in Asia’s online social networking space, on its acquisition of Happn, a French location-based social search mobile and web application that enables users to connect with others based on their proximity and interests.

Cooley advised AusperBio, a privately held, clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), on its $63 million Series B2 financing.

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).